History
| Oct. | 1995 | Founded in Nishi-Shimbashi, Minato-ku, Tokyo, with the aim of providing a new medical support business in preventive medicine (capital:JPY10 million). |
|---|---|---|
| Apr. | 1999 | Established Institute of Molecular Immunology in Seta, Setagaya-ku, Tokyo, constructed Cell Processing Center for Seta Clinic (Seta CPC), and started providing its core business Immuno-Cell Therapy Total Support Service. |
| Dec. | 2000 | Relocated its Head Office to Shimbashi, Minato-ku, Tokyo. |
| Aug. | 2001 | Ministry of Health, Labour and Welfare approved "Project for development ofnew business fields" under the Act for Facilitating the Creation of New Business. |
| Oct. | 2001 | Relocated its Head Office to Shin-Yokohama, Kohoku-ku, Yokohama, constructed Shin-Yokohama CPC1, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. |
| Apr. | 2002 | Established Institute of Medical Science at Kohoku-ku, Yokohama-shi, Kanagawa. |
| Jul. | 2002 | Established Shin-Yokohama CPC2 for contracted Medical Institutions. |
| May | 2003 | Newly established Research and Development Center at Tamagawadai, Setagaya-ku, Tokyo. Transferred the Institute of Molecular Immunology and the Institute of Medical Science to the new institute, and renamed the latter to “Institute of Molecular Genetics.” |
| Jun. | 2003 | Established Osaka Office in Esaka-cho, Suita-shi, Osaka, constructed Osaka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. |
| Jul. | 2003 | Received 1st "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry. |
| Oct. | 2003 | Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.
MEDINET's shares were listed on Tokyo Stock Exchange (Mothers: 2370) (as of Oct. 8, 2003). |
| Mar. | 2004 | International Organization for Standardization certified ISO9001 Certification for quality management of cell culturing and processing. |
| May | 2004 | Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to "Medinet Medical Institute." |
| Aug. | 2004 | Started providing new cancer tissue storage service Self Cancer Cell Depository™. |
| Feb. | 2007 | Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the "Department of Immunotherapeutics" established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital. |
| Jun. | 2007 | Concluded a license agreement with the National Hospital Organization Osaka Medical Center for immuno-cell therapy technological support at the center. |
| Nov. | 2007 | Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to "Research and Development Center." |
| Jan. | 2008 | Established Institute of Medical Service Management, Inc. |
| Jul. | 2011 | Started Providing Immuno-Cell Therapy Total Support Service to Kyushu University's Center for Advanced Medical Innovation. |
| Apr. | 2012 | Established the cooperative research department "Department of Advanced Molecular and Cell Therapy" in Kyushu University Center for Advanced Medical Innovation. |
| Jul. | 2012 | Started providing its service to the University of Tokyo Hospital which provides autologous γδT lymphocytes in patients with non-small cell lung cancer as advanced medical treatment. |
| Dec. | 2013 | Established a wholly owned subsidiary "MEDcell Co., Ltd.", for the Cell Medicinal Product Business.
For expansion of the "Contract Cell Manufacturing Business," established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF). |
| May | 2015 | Obtained license for the manufacture of specified cell products in Shinagawa CPF. |
| Jun. | 2016 | Transferred the entire R&D function from Tamagawadai, Setagaya-ku, Tokyo to its Head Office. |
| Oct. | 2016 | Contracted cell processing business at Ibaraki Children's Hospital. |
| May. | 2017 | Agreement with the Kenkoigaku Association on the manufacture of specified cell products. |
| Oct. | 2017 | Received regulatory approval to manufacture specified cell products at its Shin-Yokohama Cell Processing Center and Osaka Cell Processing Center. |
| Oct. | 2017 | Agreement with Miwa Central Clinic regarding manufacturing of specified cell products. |
| Dec. | 2017 | Entered into license agreement with Histogenics Corporation for Development and Commercialization of NeoCart for the Japanese Market. |
| Mar. | 2018 | With the National Hospital Organization concluded a joint development agreement with the goal of obtaining approval to manufacture and sell as a regenerative medicinal product ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL). |
| Aug. | 2018 | Integrated Osaka CPC into Shin-Yokohama CPC. |
| Aug. | 2018 | Conducted an absorption-type merger of two consolidated subsidiaries, Institute of Medical Service Management, Inc. and MEDcell Co., Ltd. The merger took effect on October 1, 2018. |
| Dec. | 2018 | Signed a contract development agreement with JUNTEN BIO Co.,Ltd. for technology to manufacture regenerative medicinal products. |
| Jan. | 2019 | Concluded a licensing agreement with BioLegend, Inc., which is headquartered in the US, for the development of research products using one of our novel monoclonal antibodies. |
| Apr. | 2019 | Integrated Shin-Yokohama CPC into Shinagawa CPF. |
| Jun. | 2019 | Relocated its Head Office to Heiwajima, Ota-ku, Tokyo. |
| Oct. | 2019 | Signed a licensing agreement with Taiwanese listed biopharmaceutical company Medigen Biotechnology Corp. regarding gamma-delta T cell culture technology. |
| Oct. | 2019 | Signed a joint research agreement with the National Cancer Center. |
| Nov. | 2019 | Signed a joint research agreement with the Kyoto Prefectural University of Medicine and patent joint application. |
| Nov. | 2019 | Signed a joint research agreement with National University Corporation Kyushu University. |
| Jan. | 2020 | Obtained license for the manufacture of regenerative medicinal products in Shinagawa CPF. |
| Apr. | 2022 | Transitioned from Tokyo Stock Exchange Mothers market to Growth market due to the new market classification of the Tokyo Stock Exchange. |
| Feb. | 2023 | Started providing processing technology for NKT cell-activated dendritic cells. |